1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Src
  4. Src Degrader

Src Degrader

Src Degraders (12):

Cat. No. Product Name Effect Purity
  • HY-163144
    DAS-5-oCRBN
    Degrader 98.75%
    DAS-5-oCRBN is a selective and potent PROTAC degrader of c-Src kinase. DAS-5-oCRBN has antiproliferative activity in both c-Src-dependent cell lines.
  • HY-137342
    SB1-G-187
    Degrader 98.70%
    SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, IRAK1 and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker).
  • HY-155582
    BLK degrader 1
    Degrader 98.94%
    BLK degrader 1 (compound 9) is a selective degrader of B-lymphoid tyrosine kinase (BLK). BLK degrader 1 shows anticancer activity in several B-lymphoid cell lines.
  • HY-175451
    MRT-10350
    Degrader 99.10%
    MRT-10350 (Compound 2) is a cereblon-based HCK molecular glue degrader. MRT-10350 can be used for cancers like chronic myeloid leukemia and HIV-1 infections research.
  • HY-162676
    SJ45566
    Degrader 98.41%
    SJ45566 a potent and orally active PROTAC-based LCK degrader, with a DC50 of 1.21 nM. SJ45566 can be used in the research for T‑Cell Acute Lymphoblastic Leukemia.
  • HY-181050
    DFCI-002-06
    Degrader
    DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively. DFCI-002-06 retains higher anti-tumor activity than the HCK/BTK dual-target inhibitor (HY-15805), inducing apoptosis in cancer cells. DFCI-002-06 can be used for the study of MYD88 mutant B-cell malignancies.
  • HY-180928
    LCK degrader-3
    Degrader
    LCK degrader-3 (Compound 20) is a CRBN-based LCK molecular glue degrader. LCK degrader-3 can be used in the research of acute lymphoblastic leukemia.
  • HY-175463
    LCK degrader-2
    Degrader
    LCK degrader-2 (Compound 17) is a Lck Molecular glue degrader. LCK degrader-2 can be used for cancers like acute lymphoblastic leukemia (ALL) research.
  • HY-175437
    MRT-7612
    Degrader
    MRT-7612 (Compound 4) is a cereblon-based tyrosine kinases molecular glue degrader. MRT-7612 significantly induces HCK and LYN degradation, with week efficacy on LCK. MRT-7612 can be used for cancers like chronic myeloid leukemia, autoimmune and chronic inflammatory diseases research.
  • HY-175281
    SJ11646
    Degrader
    SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC50 of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)
  • HY-175280
    Lck degrader-1
    Degrader
    Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC50=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL).
  • HY-176225
    BY13
    Degrader
    BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model. Pink: SRC-3 ligand (SI-2) (HY-101447); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-176226)